Article
Medicine, General & Internal
Mallika Marar, Qi Long, Ronac Mamtani, Vivek Narayan, Neha Vapiwala, Ravi B. Parikh
Summary: This study investigated the differences in outcomes between African American and non-Hispanic White men with metastatic castration-resistant prostate cancer (mCRPC) who received first-line abiraterone therapy. The results showed that African American men had a higher overall survival when receiving first-line abiraterone compared to non-Hispanic White men. However, there was a difference in outcomes between the two groups for first-line enzalutamide treatment.
Article
Oncology
Derya Tilki, Ming-Hui Chen, Jing Wu, Hartwig Huland, Markus Graefen, Thomas Wiegel, Dirk Boehmer, Osama Mohamad, Janet E. Cowan, Felix Y. Feng, Peter R. Carroll, Bruce J. Trock, Alan W. Partin, Anthony D'Amico
Summary: The study found that adjuvant radiation therapy compared to early salvage radiation therapy significantly reduces all-cause mortality in men with adverse pathology, such as positive pelvic lymph nodes or high Gleason score prostate cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Medicine, General & Internal
E. Lin, Hans Garmo, Mieke Van Hemelrijck, Bjorn Zethelius, Par Stattin, Emil Hagstrom, Jan Adolfsson, Danielle Crawley
Summary: This study aimed to evaluate the association between GnRH agonist use, PCa diagnosis, and CVD risk in men with type 2 diabetes. The results showed that men with type 2 diabetes who received GnRH agonist for PCa had an increased risk of CVD and lower blood pressure levels.
Article
Medicine, General & Internal
Mutlay Sayan, Jiaming Huang, Wanling Xie, Ming-Hui Chen, Marian Loffredo, Elizabeth Mcmahon, Peter Orio, Paul Nguyen, Anthony V. D'Amico
Summary: This study aimed to evaluate the factors associated with a short time interval to prostate-specific antigen (PSA) failure in order to identify patients who would benefit from treatment escalation. The results showed that young age, high PSA levels, and high Gleason score were associated with a shorter time to PSA failure. These patients may benefit from treatment intensification and should be included in prospective randomized clinical trials.
Article
Oncology
Jui-Ming Liu, Chin-Yao Shen, Wallis C. Y. Lau, Shih-Chieh Shao, Kenneth K. C. Man, Ren-Jun Hsu, Chun-Te Wu, Edward Chia-Cheng Lai
Summary: This population-based cohort study in Taiwan and the UK found no significant increase in the risk of dementia in patients with prostate cancer receiving androgen deprivation therapy (ADT), suggesting no association between the use of ADT and new-onset dementia.
Article
Oncology
Jeffrey Shi Kai Chan, Yan Hiu Athena Lee, Jeremy Man Ho Hui, Kang Liu, Edward Christopher Dee, Kenrick Ng, Tong Liu, Gary Tse, Chi Fai Ng
Summary: Our study examined the impact of cardiovascular comorbidities on adverse cardiovascular outcomes in prostate cancer patients treated with androgen deprivation therapy (ADT). We analyzed data from Hong Kong patients with prostate cancer who received ADT and found that the presence of heart failure, myocardial infarction, arrhythmia, or a combination of these comorbidities was associated with increased cardiovascular risks. The number of major cardiovascular comorbidities had a prognostic impact, indicating its importance over the specific type of comorbidity.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Medicine, General & Internal
Shabbir M. H. Alibhai, Henriette Breunis, Gregory Feng, Narhari Timilshina, Aaron Hansen, Padraig Warde, Richard Gregg, Anthony Joshua, Neil Fleshner, George Tomlinson, Urban Emmenegger
Summary: This study longitudinally examined cognitive function in older men with metastatic castration-resistant prostate cancer undergoing treatment with docetaxel, abiraterone, enzalutamide, and radium Ra 223. The findings suggest that most older men do not experience significant cognitive decline in attention, executive function, and global cognition regardless of the treatment used.
Article
Oncology
Rachel B. Forster, Anders Engeland, Rune Kvale, Vidar Hjellvik, Tone Bjorge
Summary: This study aimed to investigate the association between androgen deprivation therapy (ADT) in prostate cancer patients and subsequent cardiovascular disease (CVD) and all-cause mortality. The results showed that ADT was associated with composite CVD, myocardial infarction, stroke, heart failure, and all-cause mortality. These associations persisted in patients with low and moderate CVD risk and ADT duration longer than 7 months.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Jane C. Figueiredo, Gillian Gresham, Elizabeth L. Barry, Leila A. Mott, Michael N. Passarelli, Patrick T. Bradshaw, Carlton W. Anderson, John A. Baron
Summary: This study investigated the relationship between sex hormone levels and risk of colorectal precursors in 925 men. The findings fill the gap in the research on sex hormones in men.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Oncology
Fatima Karzai, Stephanie M. Walker, Scott Wilkinson, Ravi A. Madan, Joanna H. Shih, Maria J. Merino, Stephanie A. Harmon, David J. VanderWeele, Lisa M. Cordes, Nicole Carrabba, John R. Bright, Nicolas T. Terrigino, Guinevere Chun, Marijo Bilusic, Anna Couvillon, Amy Hankin, Monique N. Williams, Rosina T. Lis, Huihui Ye, Peter L. Choyke, James L. Gulley, Adam G. Sowalsky, Baris Turkbey, Peter A. Pinto, William L. Dahut
Summary: For patients with localized intermediate- or high-risk prostate cancer, baseline mpMRI can help predict pathologic response, with low relative tumor burden at initial scan being most predictive of minimal residual disease or pathologic complete response. Tailoring patient selection based on these metrics may lead to improved outcomes in high-risk disease.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Harry Klimis, Jehonathan H. Pinthus, Nazanin Aghel, Emmanuelle Duceppe, Vincent Fradet, Ian Brown, D. Robert Siemens, Bobby Shayegan, Laurence Klotz, Patrick P. Luke, Tamim Niazi, Luke T. Lavallee, Negareh Mousavi, Robert J. Hamilton, Joseph L. Chin, Darin Gopaul, Philippe D. Violette, Margot K. Davis, Nawar Hanna, Robert Sabbagh, Osnat Itzhaki Ben Zadok, Ludhmila Abrahao Hajjar, Ariel Galapo Kann, Rajibul Mian, Sumathy Rangarajan, Kelvin Kuan Huei, Zaza Iakobishvili, Joseph B. Selvanayagam, Alvaro Avezum, Darryl P. Leong
Summary: This study aimed to investigate the rate and correlates of poor cardiovascular risk factor control among men with prostate cancer. It found that almost all participants had at least one uncontrolled cardiovascular risk factor, with 51% having poor overall risk factor control. Not taking statins, physical frailty, need for blood pressure medication, and age were identified as key factors associated with poor overall risk factor control.
JACC: CARDIOONCOLOGY
(2023)
Review
Oncology
James Fradin, Felix J. Kim, Grace L. Lu-Yao, Eugene Storozynsky, William K. Kelly
Summary: Prostate cancer is the second leading cause of death in American men. Androgen deprivation therapy, the main treatment, has been associated with increased cardiovascular events. This review aims to identify the cardiovascular risks of androgen deprivation therapy (ADT) and suggest ways to identify high-risk patients for cardiovascular events. The review also addresses racial disparities in both prostate cancer and cardiovascular disease and provides recommendations for monitoring patients on ADT who are at high risk for cardiovascular adverse events.
Article
Oncology
Shiva M. Nair, Max Peters, Piet Kurver, Arnon Lavi, Joost J. C. Verhoeff, Jochem R. N. van der Voort van Zyp, Marieke J. van Son, Joseph L. Chin
Summary: This study compared the long-term outcomes of cryotherapy and high-intensity-focused ultrasound therapy for prostate cancer recurrence, finding no significant difference in prostate cancer-specific mortality rate between the two treatment modalities, but a higher biochemical recurrence and castration resistance rate in the high-intensity-focused ultrasound therapy group.
PROSTATE CANCER AND PROSTATIC DISEASES
(2021)
Article
Urology & Nephrology
Oliver Sartor, Theodore G. Karrison, Howard M. Sandler, Leonard G. Gomella, Mahul B. Amin, James Purdy, Jeff M. Michalski, Mark G. Garzotto, Nadeem Pervez, Alexander G. Balogh, George B. Rodrigues, Luis Souhami, M. Neil Reaume, Scott G. Williams, Raquibul Hannan, Christopher U. Jones, Eric M. Horwitz, Joseph P. Rodgers, Felix Y. Feng, Seth A. Rosenthal
Summary: This study provided long-term follow-up data on the combination therapy of androgen deprivation therapy (ADT) + external beam radiation therapy (EBRT) + docetaxel compared to ADT + EBRT in high-risk localized prostate cancer patients. After a median follow-up of 10.4 years, no significant differences in clinical outcomes were observed between the two treatment groups. These findings suggest that docetaxel may not be effective for high-risk localized prostate cancer.
Article
Oncology
Leandro Blas, Mizuki Onozawa, Masaki Shiota, Shiro Hinotsu, Shinichi Sakamoto, Yasuhide Kitagawa, Taketo Kawai, Masatoshi Eto, Haruki Kume, Hideyuki Akaza
Summary: This study examined the survival rate and risk of death from prostate cancer in men aged >= 80 y treated with primary androgen deprivation therapy. The findings suggest that immediate ADT may not be necessary for low- and intermediate-risk groups, but more efforts for curative therapy are needed for high- or very high-risk, regional, and metastatic prostate cancer patients.
Review
Urology & Nephrology
Michael Lardas, Nikos Grivas, Thomas P. A. Debray, Fabio Zattoni, Christopher Berridge, Marcus Cumberbatch, Thomas Van den Broeck, Erik Briers, Maria De Santis, Andrea Farolfi, Nicola Fossati, Giorgio Gandaglia, Silke Gillessen, Shane O'Hanlon, Ann Henry, Matthew Liew, Malcolm Mason, Lisa Moris, Daniela Oprea-Lager, Guillaume Ploussard, Olivier Rouviere, Ivo G. Schoots, Theodorus van der Kwast, Henk van der Poel, Thomas Wiegel, Peter-Paul Willemse, Cathy Y. Yuan, Jeremy P. Grummet, Derya Tilki, Roderick C. N. van den Bergh, Thomas B. Lam, Philip Cornford, Nicolas Mottet
Summary: This study systematically reviewed patient- and tumor-related prognostic factors for post-radical prostatectomy urinary incontinence (UI). The results showed that increasing age, shorter length of the membranous urethra, greater prostate volume, and higher Charlson comorbidity index were independent prognostic factors for UI within 3 months after radical prostatectomy. These factors remained predictive at 3-12 months post-surgery.
EUROPEAN UROLOGY FOCUS
(2022)
Article
Oncology
Christian D. Fankhauser, Ailsa J. Christiansen, Christian Rothermundt, Richard Cathomas, Marian S. Wettstein, Nico C. Grossmann, Josias B. Grogg, Arnoud J. Templeton, Anita Hirschi-Blickenstorfer, Anja Lorch, Silke Gillessen, Holger Moch, Joerg Beyer, Thomas Hermanns
Summary: MiR-371a-3p can detect recurrence during active surveillance of stage I GCT earlier and more reliably than standard follow-up investigations.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Giovanni Crisafulli, Andrea Sartore-Bianchi, Luca Lazzari, Filippo Pietrantonio, Alessio Amatu, Marco Macagno, Ludovic Barault, Andrea Cassingena, Alice Bartolini, Paolo Luraghi, Gianluca Mauri, Paolo Battuello, Nicola Personeni, Maria Giulia Zampino, Valeria Pessei, Pietro Paolo Vitiello, Federica Tosi, Laura Idotta, Federica Morano, Emanuele Valtorta, Emanuela Bonoldi, Giovanni Germano, Federica Di Nicolantonio, Silvia Marsoni, Salvatore Siena, Alberto Bardelli
Summary: The use of TMZ therapy in mCRC patients can induce MMR gene defects and TMB increase, leading to disease stabilization in a subset of patients.
Article
Multidisciplinary Sciences
Roman Adam, Ariadna Tibau, Consolacion Molto Valiente, Bostjan Seruga, Alberto Ocana, Eitan Amir, Arnoud J. Templeton
Summary: Only around half of the recently approved cancer drugs in Switzerland meet the criteria for substantial clinical benefit, and there is at best only moderate concordance between the grading systems.
Review
Urology & Nephrology
Anne Neuenschwander, Chiara Lonati, Luca Antonelli, Alexandros Papachristofilou, Richard Cathomas, Christian Rothermundt, Arnoud J. Templeton, Aziz Gulamhusein, Stefanie Fischer, Silke Gillessen, Thomas Hermanns, Anja Lorch, Agostino Mattei, Christian D. Fankhauser
Summary: This study reviewed the literature on the oncological outcomes of primary retroperitoneal lymph node dissection (RPLND) in men with stage II nonseminomatous germ cell tumor (NSGCT). The results showed that RPLND can provide accurate staging and may offer a cure in selected patients. However, the existing literature is heterogeneous and a meta-analysis was not possible.
EUROPEAN UROLOGY FOCUS
(2023)
Article
Oncology
Silke Gillessen, Giuseppe Procopio, Stefanie Hayoz, Eloise Kremer, Michael Schwitter, Orazio Caffo, David Lorente, Augusto Pedrazzini, Guilhem Roubaud, Soazig Nenan, Aurelius Omlin, Consuelo Buttigliero, Juan Ignacio Delgado Mingorance, Aranzazu Gonzalez-del-Alba, Maria Teresa Delgado, Franco Nole, Fabio Turco, Ricardo Pereira Mestre, Karin Ribi, Richard Cathomas
Summary: Darolutamide maintenance after successful taxane chemotherapy shows promising efficacy and safety in patients with metastatic castration-resistant prostate cancer (mCRPC).
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Emre Yekedüz, Rana R. McKay, Silke Gillessen, Toni K. Choueiri, Yuksel Ürün
Summary: This review evaluates the impact of abiraterone acetate plus prednisone versus non-steroidal anti-androgens on overall survival for metastatic castration-sensitive prostate cancer with visceral metastasis. The analysis shows that abiraterone acetate improves overall survival in patients with visceral metastasis, while second-generation non-steroidal anti-androgens do not provide the same benefit in this population. However, both abiraterone acetate and second-generation non-steroidal anti-androgens improve overall survival in patients without visceral metastasis.
Article
Oncology
Ken Kudura, Nando Ritz, Arnoud J. Templeton, Marc Kissling, Tim Kutzker, Robert Foerster, Martin H. K. Hoffmann, Kwadwo Antwi, Michael C. Kreissl
Summary: The frequency of additional primary malignancies detected incidentally on FDG-PET/CT at staging in NSCLC patients was assessed, as well as their impact on patient management and survival. FDG-PET/CT performed for staging can be a valuable tool to identify additional primary tumors in NSCLC patients. The early detection of additional primary tumors and interdisciplinary patient management may lead to similar survival rates as patients with NSCLC only.
Article
Oncology
Gerhardt Attard, Laura Murphy, Noel W. Clarke, Ashwin Sachdeva, Craig Jones, Alex Hoyle, William Cross, Robert J. Jones, Christopher C. Parker, Silke Gillessen, Adrian Cook, Chris Brawley, Clare Gilson, Hannah Rush, Hoda Abdel-Aty, Claire L. Amos, Claire Murphy, Simon Chowdhury, Zafar Malik, J. Martin Russell, Nazia Parkar, Cheryl Pugh, Carlos Diaz-Montana, Carmel Pezaro, Warren Grant, Helen Saxby, Ian Pedley, Joe M. O'Sullivan, Alison Birtle, Joanna Gale, Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzouebi, Omi Parikh, Angus Robinson, Amir H. Montazeri, James Wylie, Anjali Zarkar, Richard Cathomas, Michael D. Brown, Yatin Jain, David P. Dearnaley, Malcolm D. Mason, Duncan Gilbert, Ruth E. Langley, Robin Millman, David Matheson, Matthew R. Sydes, Louise C. Brown, Mahesh K. B. Parmar, Nicholas D. James
Summary: This study analyzed two open-label, randomized, controlled phase 3 trials and evaluated the long-term outcomes and survival benefits of combining abiraterone and enzalutamide with androgen deprivation therapy in metastatic prostate cancer patients. The results showed that the combination of abiraterone and enzalutamide did not improve survival compared to androgen deprivation therapy alone, but the addition of abiraterone to androgen deprivation therapy had clinically significant improvements in survival.
Article
Integrative & Complementary Medicine
Tiffany Schlegel, Stefan Haegele-Link, Corrado Bertotto, Urte Rieger, Sophia Wittchow, Marc Schlaeppi, Arnoud Templeton
Summary: This study characterizes the disease and treatment characteristics of adult patients treated at the Center for Integrative Medicine in a Swiss hospital. The most common diagnosis is cancer, followed by pain diagnoses. The findings provide a basis for future planning of integrative medicine services.
COMPLEMENTARY MEDICINE RESEARCH
(2023)
Letter
Urology & Nephrology
Stefanie Fischer, Christian Rothermundt, Odile Stalder, Angelika Terbuch, Thomas Hermanns, Deborah Zihler, Beat Mueller, Christian D. Fankhauser, Anita Hirschi-Blickenstorfer, Bettina Seifert, Luis Alex Kluth, Mark -Peter Ufe, Walter Mingrone, Arnoud J. Templeton, Natalie Fischer, Sacha Rothschild, Regina Woelky, Silke Gillessen, Richard Cathomas
Summary: The study assessed the validity of tumor markers in detecting relapse in testicular cancer patients and found that the accuracy of conventional tumor markers is limited, particularly lactate dehydrogenase (LDH) should be questioned in routine follow-up.
EUROPEAN UROLOGY OPEN SCIENCE
(2023)
Meeting Abstract
Oncology
S. Fischer, C. Rothermundt, O. Stalder, A. Terbuch, T. Hermanns, D. Zihler, B. Mueller, A. Hirschi-Blickenstorfer, B. Seifert, L. A. Kluth, M. - P. Ufe, W. Mingrone, A. Templeton, N. Fischer, S. Rothschild, J. Beyer, R. Woelky, S. Gillessen, R. Cathomas
ONCOLOGY RESEARCH AND TREATMENT
(2022)
Meeting Abstract
Urology & Nephrology
A. Neuenschwander, C. Lonati, A. Papachristofilou, R. Cathomas, C. Rothermund, A. J. Templeton, A. Gulamhusein, S. Fischer, S. Gillessen, T. Hermanns, A. Mattei, A. Lorch, C. D. Fankhauser
Meeting Abstract
Urology & Nephrology
R. Servant, Z. Diamantopoulou, M. Garioni, L. Roma, T. Vlajnic, A. J. Templeton, H. Pueschel, S. Piscuoglio, N. Aceto, L. Bubendorf, H. Seifert, C. A. Rentsch, C. Le Magnen
Article
Urology & Nephrology
Manolis Pratsinis, Christian Fankhauser, Katerina Pratsinis, Jorg Beyer, Emanuel Buhrer, Richard Cathomas, Natalie Fischer, Thomas Hermanns, Anita Hirschi-Blickenstorfer, Jorn Kamradt, Luis AleX Kluth, Deborah Zihler, Walter Mingrone, Beat Muller, Tim Nestler, Sacha I. Rothschild, Bettina Seifert, Arnoud J. Templeton, Angelika Terbuch, Mark-Peter Ufen, Regina Woelky, Silke Gillessen, Christian Rothermundt
Summary: Incidental detection of urogenital tumors has increased due to imaging technologies. Active surveillance is a valid treatment option for low-risk prostate cancer, small renal masses, and small testicular masses. However, little is known about the behavior of small testicular germ cell tumors (GCTs), and this study highlights the metastatic potential of small testicular GCTs, raising questions about the safety of active surveillance.
EUROPEAN UROLOGY OPEN SCIENCE
(2022)